Literature DB >> 26206798

Genetic variants and cell-free hemoglobin processing in sickle cell nephropathy.

Santosh L Saraf1, Xu Zhang2, Binal Shah2, Tamir Kanias3, Krishnamurthy P Gudehithlu4, Rick Kittles5, Roberto F Machado6, Jose A L Arruda7, Mark T Gladwin3, Ashok K Singh4, Victor R Gordeuk1.   

Abstract

Intravascular hemolysis and hemoglobinuria are associated with sickle cell nephropathy. ApoL1 is involved in cell-free hemoglobin scavenging through association with haptoglobin-related protein. APOL1 G1/G2 variants are the strongest genetic predictors of kidney disease in the general African-American population. A single report associated APOL1 G1/G2 with sickle cell nephropathy. In 221 patients with sickle cell disease at the University of Illinois at Chicago, we replicated the finding of an association of APOL1 G1/G2 with proteinuria, specifically with urine albumin concentration (β=1.1, P=0.003), observed an even stronger association with hemoglobinuria (OR=2.5, P=4.3×10(-6)), and also replicated the finding of an association with hemoglobinuria in 487 patients from the Walk-Treatment of Pulmonary Hypertension and Sickle cell Disease with Sildenafil Therapy study (OR=2.6, P=0.003). In 25 University of Illinois sickle cell disease patients, concentrations of urine kidney injury molecule-1 correlated with urine cell-free hemoglobin concentrations (r=0.59, P=0.002). Exposing human proximal tubular cells to increasing cell-free hemoglobin led to increasing concentrations of supernatant kidney injury molecule-1 (P=0.01), reduced viability (P=0.01) and induction of HMOX1 and SOD2. HMOX1 rs743811 associated with chronic kidney disease stage (OR=3.0, P=0.0001) in the University of Illinois cohort and end-stage renal disease (OR=10.0, P=0.0003) in the Walk-Treatment of Pulmonary Hypertension and Sickle cell Disease with Sildenafil Therapy cohort. Longer HMOX1 GT-tandem repeats (>25) were associated with lower estimated glomerular filtration rate in the University of Illinois cohort (P=0.01). Our findings point to an association of APOL1 G1/G2 with kidney disease in sickle cell disease, possibly through increased risk of hemoglobinuria, and associations of HMOX1 variants with kidney disease, possibly through reduced protection of the kidney from hemoglobin-mediated toxicity. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26206798      PMCID: PMC4591759          DOI: 10.3324/haematol.2015.124875

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  69 in total

1.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

2.  Biomarkers for early detection of sickle nephropathy.

Authors:  Nambirajan Sundaram; Michael Bennett; Jamie Wilhelm; Mi-Ok Kim; George Atweh; Prasad Devarajan; Punam Malik
Journal:  Am J Hematol       Date:  2011-05-31       Impact factor: 10.047

Review 3.  Genetics of kidney failure and the evolving story of APOL1.

Authors:  David J Friedman; Martin R Pollak
Journal:  J Clin Invest       Date:  2011-09-01       Impact factor: 14.808

4.  Plasma hemoglobin and hemoglobin fractions in sickle cell crisis.

Authors:  H N Naumann; L W Diggs; L Barreras; B J Williams
Journal:  Am J Clin Pathol       Date:  1971-08       Impact factor: 2.493

5.  MYH9 and APOL1 are both associated with sickle cell disease nephropathy.

Authors:  Allison E Ashley-Koch; Emmanuel C Okocha; Melanie E Garrett; Karen Soldano; Laura M De Castro; Jude C Jonassaint; Eugene P Orringer; James R Eckman; Marilyn J Telen
Journal:  Br J Haematol       Date:  2011-09-13       Impact factor: 6.998

6.  Renal disease in adult Nigerians with sickle cell anemia: a report of prevalence, clinical features and risk factors.

Authors:  R A Bolarinwa; K S Akinlade; M A O Kuti; O O Olawale; N O Akinola
Journal:  Saudi J Kidney Dis Transpl       Date:  2012-01

7.  APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy.

Authors:  Jeffrey B Kopp; George W Nelson; Karmini Sampath; Randall C Johnson; Giulio Genovese; Ping An; David Friedman; William Briggs; Richard Dart; Stephen Korbet; Michele H Mokrzycki; Paul L Kimmel; Sophie Limou; Tejinder S Ahuja; Jeffrey S Berns; Justyna Fryc; Eric E Simon; Michael C Smith; Howard Trachtman; Donna M Michel; Jeffrey R Schelling; David Vlahov; Martin Pollak; Cheryl A Winkler
Journal:  J Am Soc Nephrol       Date:  2011-10-13       Impact factor: 10.121

8.  Heme oxygenase-1 gene promoter polymorphism is associated with reduced incidence of acute chest syndrome among children with sickle cell disease.

Authors:  Christopher J Bean; Sheree L Boulet; Dorothy Ellingsen; Meredith E Pyle; Emily A Barron-Casella; James F Casella; Amanda B Payne; Jennifer Driggers; Heidi A Trau; Genyan Yang; Kimberly Jones; Solomon F Ofori-Acquah; W Craig Hooper; Michael R DeBaun
Journal:  Blood       Date:  2012-09-10       Impact factor: 22.113

9.  Albuminuria correlates with hemolysis and NAG and KIM-1 in patients with sickle cell anemia.

Authors:  Dima Hamideh; Vimal Raj; Thomas Harrington; Hua Li; Emilio Margolles; Folasade Amole; Monica Garcia-Buitrago; Phillip Ruiz; Gaston Zilleruelo; Ofelia Alvarez
Journal:  Pediatr Nephrol       Date:  2014-06-03       Impact factor: 3.714

10.  Mechanisms of glomerular albumin filtration and tubular reabsorption.

Authors:  Akihiro Tojo; Satoshi Kinugasa
Journal:  Int J Nephrol       Date:  2012-05-20
View more
  34 in total

1.  Hyperfiltration predicts long-term renal outcomes in humanized sickle cell mice.

Authors:  Malgorzata Kasztan; Brandon M Fox; Jeffrey D Lebensburger; Kelly A Hyndman; Joshua S Speed; Jennifer S Pollock; David M Pollock
Journal:  Blood Adv       Date:  2019-05-14

Review 2.  Heme Oxygenase-1 in Kidney Health and Disease.

Authors:  Jeremie M Lever; Ravindra Boddu; James F George; Anupam Agarwal
Journal:  Antioxid Redox Signal       Date:  2016-05-26       Impact factor: 8.401

Review 3.  New insights into sickle cell disease: mechanisms and investigational therapies.

Authors:  Gregory J Kato
Journal:  Curr Opin Hematol       Date:  2016-05       Impact factor: 3.284

4.  HMOX1 and acute kidney injury in sickle cell anemia.

Authors:  Santosh L Saraf; Maya Viner; Ariel Rischall; Rasha Raslan; Binal N Shah; Xu Zhang; Jin Han; Michel Gowhari; Shivi Jain; Robert E Molokie; Roberto F Machado; James P Lash; Victor R Gordeuk
Journal:  Blood       Date:  2018-08-23       Impact factor: 22.113

5.  APOL1, α-thalassemia, and BCL11A variants as a genetic risk profile for progression of chronic kidney disease in sickle cell anemia.

Authors:  Santosh L Saraf; Binal N Shah; Xu Zhang; Jin Han; Bamidele O Tayo; Taimur Abbasi; Adam Ostrower; Elizabeth Guzman; Robert E Molokie; Michel Gowhari; Johara Hassan; Shivi Jain; Richard S Cooper; Roberto F Machado; James P Lash; Victor R Gordeuk
Journal:  Haematologica       Date:  2016-09-22       Impact factor: 9.941

Review 6.  Chronic organ failure in adult sickle cell disease.

Authors:  Elliott Vichinsky
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

7.  End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings.

Authors:  Ann T Farrell; Julie Panepinto; Ankit A Desai; Adetola A Kassim; Jeffrey Lebensburger; Mark C Walters; Daniel E Bauer; Rae M Blaylark; Donna M DiMichele; Mark T Gladwin; Nancy S Green; Kathryn Hassell; Gregory J Kato; Elizabeth S Klings; Donald B Kohn; Lakshmanan Krishnamurti; Jane Little; Julie Makani; Punam Malik; Patrick T McGann; Caterina Minniti; Claudia R Morris; Isaac Odame; Patricia Ann Oneal; Rosanna Setse; Poornima Sharma; Shalini Shenoy
Journal:  Blood Adv       Date:  2019-12-10

Review 8.  The spectrum of sickle hemoglobin-related nephropathy: from sickle cell disease to sickle trait.

Authors:  Rakhi P Naik; Vimal K Derebail
Journal:  Expert Rev Hematol       Date:  2017-10-30       Impact factor: 2.929

9.  Sustained treatment of sickle cell mice with haptoglobin increases HO-1 and H-ferritin expression and decreases iron deposition in the kidney without improvement in kidney function.

Authors:  Patricia A Shi; Erika Choi; Narendranath R Chintagari; Julia Nguyen; Xinhua Guo; Karina Yazdanbakhsh; Narla Mohandas; Abdu I Alayash; Elizabeth A Manci; John D Belcher; Gregory M Vercellotti
Journal:  Br J Haematol       Date:  2016-08-10       Impact factor: 6.998

Review 10.  Minireview: Genetic basis of heterogeneity and severity in sickle cell disease.

Authors:  Alawi Habara; Martin H Steinberg
Journal:  Exp Biol Med (Maywood)       Date:  2016-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.